Uracyl spirooxetane nucleosides

Abstract

The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R 9 has the meaning as defined herein,or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.

1 . A compound of formula I: 
       
         
           
           
               
               
           
         
         including any possible stereoisomer thereof, wherein: 
         R 9  is C 1 -C 6 alkyl, phenyl, C 3 -C 7 cycloalkyl or C 1 -C 3 alkyl substituted with 1, 2 or 3 substituents each independently selected from phenyl, naphtyl, C 3 -C 6 cycloalkyl, hydroxy, or C 1 -C 6 alkoxy; 
         or a pharmaceutically acceptable salt or solvate thereof. 
       
     
     
         2 . A compound according to  claim 1  which is of formula Ia: 
       
         
           
           
               
               
           
         
       
     
     
         3 . A compound according to  claim 1 , wherein R 9  is C 1 -C 6 alkyl or C 1 -C 2 alkyl substituted with phenyl, C 1 -C 2 alkoxy or C 3 -C 6 cycloalkyl. 
     
     
         4 . A compound according to  claim 1 , wherein R 9  is C 2 -C 4 alkyl. 
     
     
         5 . A compound according to  claim 1 , wherein R 9  is i-propyl. 
     
     
         6 . A compound according to  claim 1 , which is of formula Ib: 
       
         
           
           
               
               
           
         
       
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . A compound of formula VI: 
       
         
           
           
               
               
           
         
         including any stereochemical form, pharmaceutically acceptable salt or solvate thereof. 
       
     
     
         10 . A pharmaceutical composition comprising a compound according to  claim 1 , and a pharmaceutically acceptable carrier. 
     
     
         11 . (canceled) 
     
     
         12 . A compound according to  claim 1  for use in the prevention or treatment of an HCV infection in a mammal. 
     
     
         13 . A product containing (a) a compound of formula I as defined in  claim 1 , and (b) another HCV inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of HCV infections.